Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.

ABSTRACT: In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.

SUBMITTER: Domachowske JB 

PROVIDER: S-EPMC10469583 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature